Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib and Cetuximab in Recurrent/Metastatic HNSCC and cSCC
NCT03524326Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2018
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenvatinib in head and neck squamous cell carcinoma (HNSCC) and cutaneous squamous cell carcinoma (cSCC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Apr 2018; status: completed.
02
Drugs
lenvatinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT03524326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03524326.